Experimental study of the liposomal form of fenoterol after improving the method of obtaining it

  • Authors: Ustinova T.M.1, Vengerovich N.2,3, Judin M.A.4
  • Affiliations:
    1. Institute of Military Medicine, Russian Federation of Ministry of Defense, Saint-Petersburg, Russia
    2. State Research Institute of Military Medicine, Russian Federation of Ministry of Defense
    3. Saint Petersburg State Chemical Pharmaceutical Universit of Ministry of health, St.-Petersburg
    4. State Scientific Research Test Institute of Military Medicine
  • Issue: Vol 2, No 2 (2020)
  • Pages: 30-37
  • Section: Pharmaceutical Sciences
  • URL: https://journals.eco-vector.com/PharmForm/article/view/34272
  • DOI: https://doi.org/10.17816/phf34272
  • Cite item

Abstract


The effect of different concentrations of cryoprotector (sucrose) on the efficiency of fenoterol inclusion in the lipid matrix during lyophilization has been studied. It has been shown that the liposomal form with the content of cryoprotector in the internal environment of liposomes – 2.5 % and in the external environment equal to 2 % provides long-term preservation of the drug in the liposome cavity. Under these conditions, it is possible to achieve a monodisperse distribution of particles with an average diameter of 4.28±1.62 μm. The assumed quantitative composition of the cryoprotector ensures the manufacturability of the liposome production process, increases the stability of the lyophilizate structure and prevents the particles from sticking together, ensuring their uniformity.

The profile of two-stage release of fenoterol from the liposomal form has been shown in vitro. The first stage of rapid release was characterized by a transition to free form within 15 minutes to 42 % of the encapsulated fenoterol. At the second stage, the active principle was released more slowly for 480 minutes.

The model of bronchospasm induced by 1% histamine has shown the advantage of the liposomal form of fenoterol in comparison with its free form in the form of an aqueous solution. Intra-tracheal administration of the liposomal form of fenoterol at a dose of 17 ukg/kg provided for 360 minutes the preservation of external respiratory function at the level of initial values, despite histamine inhalation, while the duration of action of fenoterol did not exceed 120 minutes.


About the authors

Tatiana M. Ustinova

Institute of Military Medicine, Russian Federation of Ministry of Defense, Saint-Petersburg, Russia

Author for correspondence.
Email: gniiivm_15@mil.ru
ORCID iD: 0000-0001-9579-9190
SPIN-code: 7247-4663
Scopus Author ID: 57196118429

Russian Federation

Ph.D. in Biology, Scientific Researcher at State Research Institute 

Nikolai Vengerovich

State Research Institute of Military Medicine, Russian Federation of Ministry of Defense; Saint Petersburg State Chemical Pharmaceutical Universit of Ministry of health, St.-Petersburg

Email: nikolai.vengerovich@pharminnotech.com
ORCID iD: 0000-0003-3219-341X
SPIN-code: 6690-9649
Scopus Author ID: 55639823300
ResearcherId: U-3467-2019

Russian Federation

Doctor of Medicine (MD), Professor of the Industrial Ecology Department, Deputy Head of Department, State Research Institute

Mikhail A. Judin

State Scientific Research Test Institute of Military Medicine

Email: mikhail.judin@gmail.com
SPIN-code: 4763-9666
Scopus Author ID: 53265350500

Russian Federation

Doctor of Medicine (MD),Assisting professor of Toxicology and Experimental Medicine Department, Chief of Department, State Research Institute of Military Medicine

References

  1. Хроническая обструктивная болезнь легких / Российское респираторное общество // министерство зравоохранения Российской Федерации. – 2018. – 76 с.
  2. Лебедева, М.В. Тройная терапия двумя длительно действующими бронходилататорами и ингаляционным глюкокортикостероидом при ХОБЛ / М.В. Лебедева, М.Ю. Бровко, С.В. Моисеев // клиническая фармакология и терапия. – 2019. – Т. 28, № 1. – С. 50-56.
  3. Чучалин, А.Г. Российское респираторное общество Федеральные клинические рекомендации по диагностике и лечению хронической обструкции болезни легких / А.Г. Чучалин, С.Н. Авдеев, З.Р. Авдеев [и др.] // Пульмонология. – 2014. – Т.3. – С.15-36.
  4. Janjua, S. Inhaled Steroids With and Without Regular Formoterol for Asthma: Serious Adverse Events Full text links / S. Janjua, S. Schmidt, M. Ferrer, C. J Cates // Cochrane Database Syst Rev. – 2019. – V.25, № 9. – P. 9.
  5. Kopsaftis, Z.A. Short-acting bronchodilators for the management of acute exacerbations of chronic obstructive pulmonary disease in the hospital setting: systematic review / Z.A. Kopsaftis, N.S. Sulaiman, O. D. Mountain and et.al. // Systematic Reviews. – 2018. V. 7. – 13 p.
  6. Ong, H. X. Liposomes for Inhalation / H. X. Ong, P. Young // isam textbook of aerosol medicine. – 2015. – chapter 7. – P. 303-329.
  7. Hamedinasab H, Rezayan AH, Mellat M. Development of chitosan-coated liposomalfor pulmonary delivery of N-acetylcysteine. Int J Biol Macromol. 2019; 19: S0141–8130.
  8. Dogbe MG, Mafilaza AY, Eleuterio CV. Pharmaceutical Benefits of Fluticasone Propionate Association to Delivery Systems: In Vitvo and In Vivo Evolution. Pharmaceutics. 2019; 11 (10): 521.
  9. Pomin VN. Maine non-gycosaminglysan sulfated glycans as potential pharmaceuticals. Pharm. 2015; 8 (4): 848-64.
  10. Franzé, S. Lyophilization of Liposomal Formulations: Still Necessary, Still Challenging / S. Franzé, F. Selmin, E. Samaritani and et. al. // Pharmaceutics. – 2018. – V.10, № 3. – P. 139.
  11. Аршинова, О.Ю. Особенности лиофилизации липосомальных лекарственных препаратов (Обзор) / О.Ю. Аршинова, Е.В. Санарова, А.В. Ланцова // Химико-фармацевтический журнал. – 2012. – Т.46. – №4. – С. 29-34.
  12. Wang, Y. Lyophilized liposome-based parenteral drug development: Reviewing complex product design strategies and current regulatory environments / Y. Wang, D. W. Grainger // Advanced Drug Delivery Reviews. – 2019. – V. 151–152. – P. 56-71.
  13. Краснопольский, Ю.М. Фармацевтическая биотехнология: Бионанотехнология в фармации и медицине: учеб. пособие / Ю.М. Краснопольский, А.С. Дудниченко, В.И. Швец. – Харьков: НТУ «ХПИ», 2011. – 228 с.
  14. Блынская, Е.В. Технологичнские подходы к совершенсвованию процесса лиофилизации белковых и пептидных лекарственных препаратов / Е.В. Блынская, С.В. Тишко, К.В. Алексеев // Российский биотерапевтический журнал. – 2017. – Т. 16. – С. 6-11.
  15. Wolfe J, Bryant G. Freezing, drying, and/or vitrification of membrane-solute-water systems. Cryobiology. 1999; 39: 103-29.
  16. Чан, Иен Тхи Хай. Липосомальная лекарственная форма фотодитазина / Чан Тхи Хай Иен, В.И. Поздеев, Г.А. Меерович // Российский биотерапевтический журнал. – 2010. – Т.2. – № 9. – С. 105-107.
  17. Mulyadi, N. A. Physical Characterization of Liposomes Formulation Lyophilized in the Presence of Disaccharide and HPMC as Dispersed Matrix / N. A. Mulyadi, N. Rosita, H. Yusuf // Journal of Biomimetics, Biomaterials and Biomedical Engineering. – 2017. – V.33. – P. 88-94.
  18. Fritze A, Hens F, Kimpfler A, et al. Remote loading of doxorubicin into liposomes driven by a transmembdrane phosphate gradient. Biochimica et Biophisica Acta. 2006; 1758: 1633-40.
  19. Ju, R-J Preparation and Characterization of Drug Liposomes by Ammonium Sulfate Gradient / R-J Ju, X-T Li // Liposome-Based Drug Delivery Systems. – 2017. – P. 1-19.

Statistics

Views

Abstract - 106

PDF (Russian) - 17

Cited-By


Article Metrics

Metrics Loading ...

PlumX

Dimensions

Refbacks

  • There are currently no refbacks.

Copyright (c) 2020 Pharmacy Formulas

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies